Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients
The prognostic performance of MammaPrint was demonstrated in early-stage clinically intermediate to high-risk BC patients. Moreover, patients with MammaPrint Low Risk tumors had good outcome regardless of treatment regimen, thus supporting personalized treatment choices.
Authors
- Oriana Ciani (ORCID: https://orcid.org/0000-0002-3607-0508)
- Christa Dreezen
- Giulia Fornaro (ORCID: https://orcid.org/0000-0003-0262-918X)
- Fabiola Giudici (ORCID: https://orcid.org/0000-0002-4160-3479)
- Daniele Generali (ORCID: https://orcid.org/0000-0003-2480-3855)
- Darina Pronin
- Carlo Azzini
- Andrea Rocca (ORCID: https://orcid.org/0000-0003-4613-8884)
- Stannie J. van den Ende
- Enrico Fiorino
- Valeria Cervoni
- Sergio Aguggini
- Nicoletta Ziglioli
- Carla Strina
- Marzia Alberio
- Martina Dester
- Manuela Milani (ORCID: https://orcid.org/0009-0007-9852-7423)
- Antonella Saracino
- Ingnazio Ciliberto
Institutions
- University of Trieste (IT)
- Centro di Riferimento Oncologico (IT)
- Agendia (Netherlands) (NL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituti Ospitalieri di Cremona (IT)
- Bocconi University (IT)
Publication Details
- Journal
- Heliyon
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e39485
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00